In 2015, I was interviewed by Stock News Now "The Wall Street View" and I recommended GW Pharma as a good investment. My powers of prognostication proved to be Perplexingly Profound!
Under the terms of the agreement, Jazz will pay $220 per American depositary share of GW Pharmaceuticals, consisting of $200 in cash and $20 in Jazz ordinary shares. The deal is valued at $6.7 billion net of GW cash.
The transaction, which has been approved by the boards of both companies, is expected to close in the second quarter.
Known for solutions that yield results, Seth Yakatan has completed or advised on acquisitions and corporate finance transactions totaling over $3 billion. He is CEO of Katan Associates International—a financial strategy and merchant banking firm specializing in commercialization and asset monetization—especially those within life-science and e-commerce sectors.